Kenneth Anderson
Kenneth Anderson
Ibogaine, 18-MC, and Addiction
Ibogaine, 18-MC, and Addiction
Ibogaine, 18-MC, and Addiction
Friday 31st July 2015
Professor Stanley D. Glick discusses ibogaine and 18-MC as potential anti-addiction drugs on Harm Reduction Radio - HAMS.
30 minutes
Informative
Thought-provoking
Raw
Engaging
Educational
About this podcast
Author:
Kenneth Anderson
Overview:
Categories:
Innovative Treatments & Recovery Paths
Sobriety Toolkit
Family Recovery from Addiction
Navigating Intimate Relationships
Nutritional Pathways to Recovery
Links:
Visit site
Episodes:
181 (View all)
Do you want to link to this podcast?
Get the buttons here!Professor Stanley D. Glick on the Potential of Ibogaine and 18-MC for Addiction Treatment
Craving is the cause of relapse and there are a number of things that can induce craving. Stress can induce craving, but probably the most common inducer of craving are stimuli or cues associated with the drug.
Ever wondered about the cutting-edge research behind addiction treatment? In this episode of 'Harm Reduction Radio - HAMS', Kenneth Anderson chats with Professor Stanley D. Glick, Ph.D., M.D., Professor Emeritus at Albany Medical College. Glick dives into his groundbreaking research on ibogaine and its congener 18-MC (18-Methoxycoronaridine) as potential anti-addiction drugs. With a focus on how these substances could reduce self-administration of addictive drugs without disrupting normal behaviors, this conversation is packed with fascinating insights.
Glick shares his surprising findings from animal studies and his collaboration with medicinal chemist Martin Kuna to develop a drug that can modulate the actions of all drugs affecting dopamine pathways. He also touches on the historical reluctance of the pharmaceutical industry to invest in addiction treatments and the importance of breaking heavily reinforced behaviors to prevent relapse. If you're curious about innovative approaches to addiction treatment, this episode is a must-listen.